US Stock MarketDetailed Quotes

STVN Stevanato Group

Watchlist
  • 19.540
  • +0.470+2.46%
Close Feb 14 16:00 ET
  • 19.540
  • 0.0000.00%
Post 16:52 ET
5.33BMarket Cap43.42P/E (TTM)

About Stevanato Group Company

Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates through the following segments: Biopharmaceutical and Diagnostic Solutions, and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy.

Company Profile

SymbolSTVN
Company NameStevanato Group
Listing DateJul 16, 2021
Issue Price21.00
Founded1980
CEOMr. Franco Moro
MarketNYSE
Employees5635
Fiscal Year Ends12-31
AddressVia Molinella 17
CityPiombino Dese
ProvincePadova
CountryItaly
Zip Code35017
Phone39-049-9318111

Company Executives

  • Name
  • Position
  • Salary
  • Franco Moro
  • Director and Chief Executive Officer
  • --
  • Marco Dal Lago
  • Chief Financial Officer
  • --
  • Mauro Stocchi
  • Chief Business Officer
  • --
  • Sergio Stevanato
  • Director and Chairman Emeritus
  • --
  • Marco Stevanato
  • Vice Chairman of the Board
  • --
  • Franco Stevanato
  • Executive Chairman of the Board
  • --
  • Riccardo Butta
  • President, Americas
  • --
  • Paola Vezzaro
  • Director
  • --
  • Fabiano Nicoletti
  • Director
  • --
  • Madhavan Balachandran
  • Director
  • --
  • Dr. Donald Eugene Morel, Jr
  • Director
  • --
  • Alvise Spinazzi
  • Director
  • --
  • William J. Federici
  • Independent Director
  • --
  • Fabio Buttignon
  • Independent Director
  • --
  • Dr. Fabrizio Bonanni
  • Independent Director
  • --

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Many institutions are bullish! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1 Show More